Pharmacology-2026

Dr. Hong graduated with top honors from Harbin Medical University and dedicated herself to internal medicine. For over a decade, she has been engaged in clinical and basic research on cardiovascular diseases, having conducted visiting research at the Mayo Clinic. She has led multiple national and provincial scientific research projects and has published more than ten SCI papers. She has received numerous national medical awards

Dr. Marek Wasiluk is a medically qualified and ISO 9000:2001 trained clinical research professional with over 25 years of experience, including 20 years in GxP auditing and quality consultancy. An expert in ICH GCP, QMS implementation, and global clinical regulations, he has conducted over 250 audits and consulting projects across 50 countries. His experience spans all clinical trial phases, FDA/EMA mock inspections, and risk-based global audits

Luis Angel Rojas, PhD, is a senior research scientist statistician with more than 35 years of experience advancing drug, biologic, and medical device programs worldwide. As CEO and President of InCSD, LLC, VP of Clinical Development for Indication Bio, and former Chief Clinical Development Officer for the Curyx Bio platform, he has led global development efforts across rare diseases, neurology, oncology, and immunology. Dr. Rojas specializes in modern

Dr. Lourdes Mónica Bravo Anaya is currently a Researcher at CNRS at the Institut des Sciences Chimiques de Rennes, France. She holds dual PhDs in Chemical Engineering and in Fluid Mechanics, Processes, and Energy from the University of Guadalajara (México) and the University of Grenoble (France), which she completed in 2015. Her postdoctoral work at LCPO (Bordeaux), LiPhy (Grenoble), and CERMAV (Grenoble) focused on biopolymers, polymer–biomacromolecu

Dr. Amosy E. M'Koma is an entrepreneur and Tenured Full Professor Emeritus of Surgery, Surgical Sciences, Pathology, and Cancer Biology, and a Principal Investigator at Me harry Medical College, Department of Biochemistry, Cancer Biology, Neuroscience, and Pharmacology. He also serves as an Adjunct Professor of Surgery at Vanderbilt University Medical Center, Division of General Surgery, Colon, and Rectal Surgery, in Nashville, Tennessee, United State

Dr. Sheila A. Mathias has more than 20 years of leadership experience in the pharmaceutical industry, accelerating drug development. She brings extensive global regulatory affairs strategic guidance and clinical development experience, having worked across a range of therapeutic areas, including pain management, addiction medicine, and dermatology. This experience has spanned big pharma, mid-sized, to start-up biotechnology companies. 

Dr. Vitali M. Boitsov is a prominent Russian chemist affiliated with Saint Petersburg State University, known for his extensive contributions to synthetic organic chemistry. His research focuses on the design and synthesis of heterocyclic and spirocyclic compounds through advanced cycloaddition reactions, including innovative [3 + 2] methodologies. Dr. Boitsov’s work has significant applications in medicinal and materials chemistry.

Peng Zhan is a Professor and Doctoral Supervisor at Shandong University. He focuses on antiviral and major chronic disease drug R&D, with 8 national-level projects. His team’s two candidate drugs entered Phase I and III clinical trials. He has published over 100 papers in Nat Commun, Cell Metab, etc., with an H-index of 51, authorized 20+ patents, and edited 6 monographs. He serves as Associate Editor of Eur J Med Chem and committee member of multiple

Prof. Tong Yin serves as the Vice Director and Doctoral Supervisor at the Institute of Geriatrics, National Clinical Research Center for Geriatric Diseases, PLA General Hospital in Beijing China. She is mainly dedicated to pharmacogenomic research and translational application for cardiovascular diseases and elderly comorbidities. 

Dr. Saloua Sahbani is an Assistant Professor at the College of Applied Medical Sciences, Taibah University (AlUla), and Head of Quality and Development since 2015. She holds two PhDs: one in Radiation Sciences and Biomedical Imaging from the University of Sherbrooke, Canada, and another in Biochemistry and Molecular Biology. Her research focuses on DNA damage and repair induced by ionizing radiation, particularly Low Energy Electrons.

Dr. Greim’s research experience is drug metabolism, toxicokinetics, mechanisms of carcinogenic agents, in vitro test systems published in over 500 peer reviewed papers. In addition to many contributions to books, two textbooks in Toxicology, in German and English, 2nd editions (Wiley 2016 and 2021), and “The cellular response to the genotoxic insult: the question of threshold for genotoxic carcinogens (Royal Society of Chemistry, London, 2012). 

Professor Jing Nie is a senior scientist at Peking University First Hospital. She obtained her PhD from Kochi University, Japan, in 1999, and completed five years of postdoctoral training at the University of Toronto, Canada. Since 2004, she has held faculty appointments in the Department of Nephrology at Sun Yat-sen University, Southern Medical University, and Peking University. She has received multiple competitive research grants, including the National Science Fund for Outstanding Young Scholars from the National Natural Science Foundation of China. Her research focuses on the pathogenesis and prevention of chronic kidney disease, with particular emphasis on risk factors, mechanisms of intrinsic renal cell injury, and therapeutic lead discovery. She has published more than 100 peer-reviewed papers in leading journals, including Science Translational Medicine, Nature Communications, EBioMedicine, Kidney International, and Cell Death & Disease.